1 Study Coverage 1.1 Anti-epileptic Drugs for Pediatrics Product Introduction 1.2 Market Segments 1.3 Key Anti-epileptic Drugs for Pediatrics Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Type 1.4.2 1st generation 1.4.3 2nd generation 1.4.4 3rd generation 1.5 Market by Application 1.5.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Application 1.5.2 Hospitals 1.5.3 Retail pharmacies 1.5.4 Online pharmacies 1.6 Study Objectives 1.7 Years Considered 2 Executive Summary 2.1 Global Anti-epileptic Drugs for Pediatrics Market Size, Estimates and Forecasts 2.1.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2015-2026 2.1.2 Global Anti-epileptic Drugs for Pediatrics Sales 2015-2026 2.2 Global Anti-epileptic Drugs for Pediatrics, Market Size by Producing Regions: 2015 VS 2020 VS 2026 2.2.1 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Anti-epileptic Drugs for Pediatrics Competitor Landscape by Players 3.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers 3.1.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2015-2020) 3.1.2 Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2015-2020) 3.2 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers 3.2.1 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2015-2020) 3.2.2 Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Anti-epileptic Drugs for Pediatrics Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Anti-epileptic Drugs for Pediatrics Revenue in 2019 3.2.5 Global Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Anti-epileptic Drugs for Pediatrics Price by Manufacturers 3.4 Anti-epileptic Drugs for Pediatrics Manufacturing Base Distribution, Product Types 3.4.1 Anti-epileptic Drugs for Pediatrics Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Anti-epileptic Drugs for Pediatrics Product Type 3.4.3 Date of International Manufacturers Enter into Anti-epileptic Drugs for Pediatrics Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Anti-epileptic Drugs for Pediatrics Market Size by Type (2015-2020) 4.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020) 4.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2015-2020) 4.1.3 Anti-epileptic Drugs for Pediatrics Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Anti-epileptic Drugs for Pediatrics Market Size Forecast by Type (2021-2026) 4.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Type (2021-2026) 4.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Type (2021-2026) 4.2.3 Anti-epileptic Drugs for Pediatrics Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Anti-epileptic Drugs for Pediatrics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Market Size by Application (2015-2026) 5.1 Global Anti-epileptic Drugs for Pediatrics Market Size by Application (2015-2020) 5.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020) 5.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2015-2020) 5.1.3 Anti-epileptic Drugs for Pediatrics Price by Application (2015-2020) 5.2 Anti-epileptic Drugs for Pediatrics Market Size Forecast by Application (2021-2026) 5.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Application (2021-2026) 5.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Application (2021-2026) 5.2.3 Global Anti-epileptic Drugs for Pediatrics Price Forecast by Application (2021-2026) 6 North America 6.1 North America Anti-epileptic Drugs for Pediatrics by Country 6.1.1 North America Anti-epileptic Drugs for Pediatrics Sales by Country 6.1.2 North America Anti-epileptic Drugs for Pediatrics Revenue by Country 6.1.3 U.S. 6.1.4 Canada 6.2 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type 6.3 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application 7 Europe 7.1 Europe Anti-epileptic Drugs for Pediatrics by Country 7.1.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Country 7.1.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia 7.2 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type 7.3 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application 8 Asia Pacific 8.1 Asia Pacific Anti-epileptic Drugs for Pediatrics by Region 8.1.1 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region 8.1.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam 8.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type 8.3 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application 9 Latin America 9.1 Latin America Anti-epileptic Drugs for Pediatrics by Country 9.1.1 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country 9.1.2 Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina 9.2 Central & South America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type 9.3 Central & South America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application 10 Middle East and Africa 10.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics by Country 10.1.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country 10.1.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 U.A.E 10.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type 10.3 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application 11 Company Profiles 11.1 Mylan N.V 11.1.1 Mylan N.V Corporation Information 11.1.2 Mylan N.V Description and Business Overview 11.1.3 Mylan N.V Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Products Offered 11.1.5 Mylan N.V Related Developments 11.2 Cephalon, Inc 11.2.1 Cephalon, Inc Corporation Information 11.2.2 Cephalon, Inc Description and Business Overview 11.2.3 Cephalon, Inc Sales, Revenue and Gross Margin (2015-2020) 11.2.4 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Products Offered 11.2.5 Cephalon, Inc Related Developments 11.3 GlaxoSmithKline plc 11.3.1 GlaxoSmithKline plc Corporation Information 11.3.2 GlaxoSmithKline plc Description and Business Overview 11.3.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020) 11.3.4 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Products Offered 11.3.5 GlaxoSmithKline plc Related Developments 11.4 Janssen Pharmaceuticals 11.4.1 Janssen Pharmaceuticals Corporation Information 11.4.2 Janssen Pharmaceuticals Description and Business Overview 11.4.3 Janssen Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020) 11.4.4 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Products Offered 11.4.5 Janssen Pharmaceuticals Related Developments 11.5 Novartis AG 11.5.1 Novartis AG Corporation Information 11.5.2 Novartis AG Description and Business Overview 11.5.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020) 11.5.4 Novartis AG Anti-epileptic Drugs for Pediatrics Products Offered 11.5.5 Novartis AG Related Developments 11.6 Pfizer, Inc 11.6.1 Pfizer, Inc Corporation Information 11.6.2 Pfizer, Inc Description and Business Overview 11.6.3 Pfizer, Inc Sales, Revenue and Gross Margin (2015-2020) 11.6.4 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Products Offered 11.6.5 Pfizer, Inc Related Developments 11.7 Sanofi S.A 11.7.1 Sanofi S.A Corporation Information 11.7.2 Sanofi S.A Description and Business Overview 11.7.3 Sanofi S.A Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Sanofi S.A Anti-epileptic Drugs for Pediatrics Products Offered 11.7.5 Sanofi S.A Related Developments 11.8 UCB Pharma Limited 11.8.1 UCB Pharma Limited Corporation Information 11.8.2 UCB Pharma Limited Description and Business Overview 11.8.3 UCB Pharma Limited Sales, Revenue and Gross Margin (2015-2020) 11.8.4 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Products Offered 11.8.5 UCB Pharma Limited Related Developments 11.9 Sunovion Pharmaceuticals Limited 11.9.1 Sunovion Pharmaceuticals Limited Corporation Information 11.9.2 Sunovion Pharmaceuticals Limited Description and Business Overview 11.9.3 Sunovion Pharmaceuticals Limited Sales, Revenue and Gross Margin (2015-2020) 11.9.4 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Products Offered 11.9.5 Sunovion Pharmaceuticals Limited Related Developments 11.10 Valeant Pharmaceuticals International, Inc 11.10.1 Valeant Pharmaceuticals International, Inc Corporation Information 11.10.2 Valeant Pharmaceuticals International, Inc Description and Business Overview 11.10.3 Valeant Pharmaceuticals International, Inc Sales, Revenue and Gross Margin (2015-2020) 11.10.4 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Products Offered 11.10.5 Valeant Pharmaceuticals International, Inc Related Developments 11.1 Mylan N.V 11.1.1 Mylan N.V Corporation Information 11.1.2 Mylan N.V Description and Business Overview 11.1.3 Mylan N.V Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Products Offered 11.1.5 Mylan N.V Related Developments 11.12 GW Pharmaceuticals 11.12.1 GW Pharmaceuticals Corporation Information 11.12.2 GW Pharmaceuticals Description and Business Overview 11.12.3 GW Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020) 11.12.4 GW Pharmaceuticals Products Offered 11.12.5 GW Pharmaceuticals Related Developments 11.13 Insys 11.13.1 Insys Corporation Information 11.13.2 Insys Description and Business Overview 11.13.3 Insys Sales, Revenue and Gross Margin (2015-2020) 11.13.4 Insys Products Offered 11.13.5 Insys Related Developments 11.14 Zynerba 11.14.1 Zynerba Corporation Information 11.14.2 Zynerba Description and Business Overview 11.14.3 Zynerba Sales, Revenue and Gross Margin (2015-2020) 11.14.4 Zynerba Products Offered 11.14.5 Zynerba Related Developments 12 Future Forecast by Regions (Countries) (2021-2026) 12.1 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Region 12.1.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Regions 2021-2026 12.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Regions 2021-2026 12.2 North America Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026) 12.2.1 North America: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026) 12.2.2 North America: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026) 12.2.3 North America: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026) 12.3 Europe Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026) 12.3.1 Europe: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026) 12.3.2 Europe: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026) 12.3.3 Europe: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026) 12.4 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Region (2021-2026) 12.5 Latin America Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026) 12.5.1 Latin America: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026) 12.5.2 Latin America: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026) 12.5.3 Latin America: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026) 12.6 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porter's Five Forces Analysis 13.5 Primary Interviews with Key Anti-epileptic Drugs for Pediatrics Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Anti-epileptic Drugs for Pediatrics Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

List of Tables Table 1. Anti-epileptic Drugs for Pediatrics Market Segments Table 2. Ranking of Global Top Anti-epileptic Drugs for Pediatrics Manufacturers by Revenue (US$ Million) in 2019 Table 3. Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million) Table 4. Major Manufacturers of 1st generation Table 5. Major Manufacturers of 2nd generation Table 6. Major Manufacturers of 3rd generation Table 7. Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Application 2020-2026 (K Units) Table 8. Global Anti-epileptic Drugs for Pediatrics Market Size by Region (K Units) & (US$ Million): 2020 VS 2026 Table 9. Global Anti-epileptic Drugs for Pediatrics Sales by Regions 2015-2020 (K Units) Table 10. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Regions (2015-2020) Table 11. Global Anti-epileptic Drugs for Pediatrics Revenue by Regions 2015-2020 (US$ Million) Table 12. Global Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2015-2020) (K Units) Table 13. Global Anti-epileptic Drugs for Pediatrics Sales Share by Manufacturers (2015-2020) Table 14. Global Anti-epileptic Drugs for Pediatrics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020) Table 15. Global Anti-epileptic Drugs for Pediatrics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-epileptic Drugs for Pediatrics as of 2019) Table 16. Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2015-2020) (US$ Million) Table 17. Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2015-2020) Table 18. Key Manufacturers Anti-epileptic Drugs for Pediatrics Price (2015-2020) (USD/Unit) Table 19. Anti-epileptic Drugs for Pediatrics Manufacturers Manufacturing Base Distribution and Headquarters Table 20. Manufacturers Anti-epileptic Drugs for Pediatrics Product Type Table 21. Date of International Manufacturers Enter into Anti-epileptic Drugs for Pediatrics Market Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans Table 23. Global Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020) (K Units) Table 24. Global Anti-epileptic Drugs for Pediatrics Sales Share by Type (2015-2020) Table 25. Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2015-2020) (US$ Million) Table 26. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Type (2015-2020) Table 27. Anti-epileptic Drugs for Pediatrics Average Selling Price (ASP) by Type 2015-2020 (USD/Unit) Table 28. Global Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020) (K Units) Table 29. Global Anti-epileptic Drugs for Pediatrics Sales Share by Application (2015-2020) Table 30. North America Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units) Table 31. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020) Table 32. North America Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million) Table 33. North America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020) Table 34. North America Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020) (K Units) Table 35. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2015-2020) Table 36. North America Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020) (K Units) Table 37. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020) Table 38. Europe Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units) Table 39. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020) Table 40. Europe Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million) Table 41. Europe Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020) Table 42. Europe Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020) (K Units) Table 43. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2015-2020) Table 44. Europe Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020) (K Units) Table 45. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020) Table 46. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region (2015-2020) (K Units) Table 47. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2015-2020) Table 48. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region (2015-2020) (US$ Million) Table 49. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2015-2020) Table 50. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020) (K Units) Table 51. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2015-2020) Table 52. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020) (K Units) Table 53. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020) Table 54. Latin America Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units) Table 55. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020) Table 56. Latin Americaa Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million) Table 57. Latin America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020) Table 58. Latin America Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020) (K Units) Table 59. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2015-2020) Table 60. Latin America Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020) (K Units) Table 61. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020) Table 62. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country (2015-2020) (K Units) Table 63. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2015-2020) Table 64. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country (2015-2020) (US$ Million) Table 65. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2015-2020) Table 66. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020) (K Units) Table 67. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2015-2020) Table 68. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020) (K Units) Table 69. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020) Table 70. Mylan N.V Corporation Information Table 71. Mylan N.V Description and Major Businesses Table 72. Mylan N.V Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 73. Mylan N.V Product Table 74. Mylan N.V Recent Development Table 75. Cephalon, Inc Corporation Information Table 76. Cephalon, Inc Description and Major Businesses Table 77. Cephalon, Inc Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 78. Cephalon, Inc Product Table 79. Cephalon, Inc Recent Development Table 80. GlaxoSmithKline plc Corporation Information Table 81. GlaxoSmithKline plc Description and Major Businesses Table 82. GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 83. GlaxoSmithKline plc Product Table 84. GlaxoSmithKline plc Recent Development Table 85. Janssen Pharmaceuticals Corporation Information Table 86. Janssen Pharmaceuticals Description and Major Businesses Table 87. Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 88. Janssen Pharmaceuticals Product Table 89. Janssen Pharmaceuticals Recent Development Table 90. Novartis AG Corporation Information Table 91. Novartis AG Description and Major Businesses Table 92. Novartis AG Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 93. Novartis AG Product Table 94. Novartis AG Recent Development Table 95. Pfizer, Inc Corporation Information Table 96. Pfizer, Inc Description and Major Businesses Table 97. Pfizer, Inc Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 98. Pfizer, Inc Product Table 99. Pfizer, Inc Recent Development Table 100. Sanofi S.A Corporation Information Table 101. Sanofi S.A Description and Major Businesses Table 102. Sanofi S.A Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 103. Sanofi S.A Product Table 104. Sanofi S.A Recent Development Table 105. UCB Pharma Limited Corporation Information Table 106. UCB Pharma Limited Description and Major Businesses Table 107. UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 108. UCB Pharma Limited Product Table 109. UCB Pharma Limited Recent Development Table 110. Sunovion Pharmaceuticals Limited Corporation Information Table 111. Sunovion Pharmaceuticals Limited Description and Major Businesses Table 112. Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 113. Sunovion Pharmaceuticals Limited Product Table 114. Sunovion Pharmaceuticals Limited Recent Development Table 115. Valeant Pharmaceuticals International, Inc Corporation Information Table 116. Valeant Pharmaceuticals International, Inc Description and Major Businesses Table 117. Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 118. Valeant Pharmaceuticals International, Inc Product Table 119. Valeant Pharmaceuticals International, Inc Recent Development Table 120. Zogenix Corporation Information Table 121. Zogenix Description and Major Businesses Table 122. Zogenix Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 123. Zogenix Product Table 124. Zogenix Recent Development Table 125. GW Pharmaceuticals Corporation Information Table 126. GW Pharmaceuticals Description and Major Businesses Table 127. GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 128. GW Pharmaceuticals Product Table 129. GW Pharmaceuticals Recent Development Table 130. Insys Corporation Information Table 131. Insys Description and Major Businesses Table 132. Insys Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 133. Insys Product Table 134. Insys Recent Development Table 135. Zynerba Corporation Information Table 136. Zynerba Description and Major Businesses Table 137. Zynerba Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020) Table 138. Zynerba Product Table 139. Zynerba Recent Development Table 140. Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Regions (2021-2026) (K Units) Table 141. Global Anti-epileptic Drugs for Pediatrics Sales Market Share Forecast by Regions (2021-2026) Table 142. Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Regions (2021-2026) (US$ Million) Table 143. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share Forecast by Regions (2021-2026) Table 144. North America: Anti-epileptic Drugs for Pediatrics Sales Forecast by Country (2021-2026) (K Units) Table 145. North America: Anti-epileptic Drugs for Pediatrics Revenue Forecast by Country (2021-2026) (US$ Million) Table 146. Europe: Anti-epileptic Drugs for Pediatrics Sales Forecast by Country (2021-2026) (K Units) Table 147. Europe: Anti-epileptic Drugs for Pediatrics Revenue Forecast by Country (2021-2026) (US$ Million) Table 148. Asia Pacific: Anti-epileptic Drugs for Pediatrics Sales Forecast by Region (2021-2026) (K Units) Table 149. Asia Pacific: Anti-epileptic Drugs for Pediatrics Revenue Forecast by Region (2021-2026) (US$ Million) Table 150. Latin America: Anti-epileptic Drugs for Pediatrics Sales Forecast by Country (2021-2026) (K Units) Table 151. Latin America: Anti-epileptic Drugs for Pediatrics Revenue Forecast by Country (2021-2026) (US$ Million) Table 152. Middle East and Africa: Anti-epileptic Drugs for Pediatrics Sales Forecast by Country (2021-2026) (K Units) Table 153. Middle East and Africa: Anti-epileptic Drugs for Pediatrics Revenue Forecast by Country (2021-2026) (US$ Million) Table 154. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 155. Key Challenges Table 156. Market Risks Table 157. Main Points Interviewed from Key Anti-epileptic Drugs for Pediatrics Players Table 158. Anti-epileptic Drugs for Pediatrics Customers List Table 159. Anti-epileptic Drugs for Pediatrics Distributors List Table 160. Research Programs/Design for This Report Table 161. Key Data Information from Secondary Sources Table 162. Key Data Information from Primary Sources List of Figures Figure 1. Anti-epileptic Drugs for Pediatrics Product Picture Figure 2. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type in 2020 & 2026 Figure 3. 1st generation Product Picture Figure 4. 2nd generation Product Picture Figure 5. 3rd generation Product Picture Figure 6. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application in 2020 & 2026 Figure 7. Hospitals Figure 8. Retail pharmacies Figure 9. Online pharmacies Figure 10. Anti-epileptic Drugs for Pediatrics Report Years Considered Figure 11. Global Anti-epileptic Drugs for Pediatrics Market Size 2015-2026 (US$ Million) Figure 12. Global Anti-epileptic Drugs for Pediatrics Sales 2015-2026 (K Units) Figure 13. Global Anti-epileptic Drugs for Pediatrics Market Size Market Share by Region: 2020 Versus 2026 Figure 14. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2015-2020) Figure 15. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region in 2019 Figure 16. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2015-2020) Figure 17. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region in 2019 Figure 18. Global Anti-epileptic Drugs for Pediatrics Sales Share by Manufacturer in 2019 Figure 19. The Top 10 and 5 Players Market Share by Anti-epileptic Drugs for Pediatrics Revenue in 2019 Figure 20. Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 21. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2015-2020) Figure 22. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type in 2019 Figure 23. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type (2015-2020) Figure 24. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type in 2019 Figure 25. Global Anti-epileptic Drugs for Pediatrics Market Share by Price Range (2015-2020) Figure 26. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2015-2020) Figure 27. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application in 2019 Figure 28. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Application (2015-2020) Figure 29. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Application in 2019 Figure 30. North America Anti-epileptic Drugs for Pediatrics Sales Growth Rate 2015-2020 (K Units) Figure 31. North America Anti-epileptic Drugs for Pediatrics Revenue Growth Rate 2015-2020 (US$ Million) Figure 32. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019 Figure 33. North America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019 Figure 34. U.S. Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 35. U.S. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 36. Canada Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 37. Canada Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 38. North America Anti-epileptic Drugs for Pediatrics Market Share by Type in 2019 Figure 39. North America Anti-epileptic Drugs for Pediatrics Market Share by Application in 2019 Figure 40. Europe Anti-epileptic Drugs for Pediatrics Sales Growth Rate 2015-2020 (K Units) Figure 41. Europe Anti-epileptic Drugs for Pediatrics Revenue Growth Rate 2015-2020 (US$ Million) Figure 42. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019 Figure 43. Europe Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019 Figure 44. Germany Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 45. Germany Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. France Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 47. France Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. U.K. Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 49. U.K. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 50. Italy Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 51. Italy Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 52. Russia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 53. Russia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 54. Europe Anti-epileptic Drugs for Pediatrics Market Share by Type in 2019 Figure 55. Europe Anti-epileptic Drugs for Pediatrics Market Share by Application in 2019 Figure 56. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Growth Rate 2015-2020 (K Units) Figure 57. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Growth Rate 2015-2020 (US$ Million) Figure 58. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Region in 2019 Figure 59. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region in 2019 Figure 60. China Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 61. China Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Japan Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 63. Japan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 64. South Korea Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 65. South Korea Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 66. India Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 67. India Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Australia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 69. Australia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. Taiwan Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 71. Taiwan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. Indonesia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 73. Indonesia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 74. Thailand Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 75. Thailand Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. Malaysia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 77. Malaysia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. Philippines Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 79. Philippines Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Vietnam Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 81. Vietnam Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 82. Asia Pacific Anti-epileptic Drugs for Pediatrics Market Share by Type in 2019 Figure 83. Asia Pacific Anti-epileptic Drugs for Pediatrics Market Share by Application in 2019 Figure 84. Latin America Anti-epileptic Drugs for Pediatrics Sales Growth Rate 2015-2020 (K Units) Figure 85. Latin America Anti-epileptic Drugs for Pediatrics Revenue Growth Rate 2015-2020 (US$ Million) Figure 86. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019 Figure 87. Latin America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019 Figure 88. Mexico Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 89. Mexico Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 90. Brazil Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 91. Brazil Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 92. Argentina Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 93. Argentina Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 94. Latin America Anti-epileptic Drugs for Pediatrics Market Share by Type in 2019 Figure 95. Latin America Anti-epileptic Drugs for Pediatrics Market Share by Application in 2019 Figure 96. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Growth Rate 2015-2020 (K Units) Figure 97. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue Growth Rate 2015-2020 (US$ Million) Figure 98. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Country in 2019 Figure 99. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country in 2019 Figure 100. Turkey Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 101. Turkey Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 102. Saudi Arabia Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 103. Saudi Arabia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 104. U.A.E Anti-epileptic Drugs for Pediatrics Sales Growth Rate (2015-2020) (K Units) Figure 105. U.A.E Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2015-2020) (US$ Million) Figure 106. Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Share by Type in 2019 Figure 107. Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Share by Application in 2019 Figure 108. North America Anti-epileptic Drugs for Pediatrics Sales Growth Rate Forecast (2021-2026) (K Units) Figure 109. North America Anti-epileptic Drugs for Pediatrics Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 110. Europe Anti-epileptic Drugs for Pediatrics Sales Growth Rate Forecast (2021-2026) (K Units) Figure 111. Europe Anti-epileptic Drugs for Pediatrics Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 112. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Growth Rate Forecast (2021-2026) (K Units) Figure 113. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 114. Latin America Anti-epileptic Drugs for Pediatrics Sales Growth Rate Forecast (2021-2026) (K Units) Figure 115. Latin America Anti-epileptic Drugs for Pediatrics Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 116. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Growth Rate Forecast (2021-2026) (K Units) Figure 117. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue Growth Rate Forecast (2021-2026) (US$ Million) Figure 118. Porter's Five Forces Analysis Figure 119. Channels of Distribution Figure 120. Distributors Profiles Figure 121. Bottom-up and Top-down Approaches for This Report Figure 122. Data Triangulation Figure 123. Key Executives Interviewed

Mylan N.V Cephalon, Inc GlaxoSmithKline plc Janssen Pharmaceuticals Novartis AG Pfizer, Inc Sanofi S.A UCB Pharma Limited Sunovion Pharmaceuticals Limited Valeant Pharmaceuticals International, Inc Zogenix GW Pharmaceuticals Insys Zynerba